Life Sciences & Healthcare: China developments 2017 and predictions 2018
You may be reflecting on what your business can expect to face this year, both in terms of opportunities and challenges in China, particularly as 2017 saw many significant developments for the Life Sciences & Healthcare sector. For example, the Chinese version of the “Orange Book” and the new drug distribution regime were both launched as well as the CFDA joining the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
In this guide, we have taken a look back at the top 10 developments of 2017 and also looked ahead to 2018 with our top 10 predictions for you and your business operating in China.
During the course of the year, we will be closely monitoring these ongoing developments and predictions, and providing you with regular updates on them through our free eAlert service, Law-Now, and also WeChat ‘CMSAsia’.
For now, we hope you find our reflections and predictions of interest and help to your business, as you continue to plan for the year ahead.
If you would like to discuss any of the developments with us, please do let us know.